Treatment of neuroblastoma cell lines with EZH2 antagonists, such as valproic acids or DZNep, can restore CASZ1 expression, inhibiting tumor cell proliferation and promoting morphological differentiation [80,81]. Here, CASZ1 is linked to neoplasm.